Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.

① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?

cls.cnApr 24 03:37 ET

Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.

① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?

cls.cnApr 21 23:57 ET

HANSOH PHARMA (03692.HK): The B7-H3 targeted antibody-drug conjugate HS-20093 has been included by the National Medical Products Administration as a breakthrough therapeutic Pharmaceutical for non-squamous non-small cell lung cancer.

On April 17, Glonghui announced that HANSOH PHARMA (03692.HK) received approval from the National Medical Products Administration (NMPA) of China on April 17, 2025, for its self-developed B7-H3 targeted antibody-drug conjugate (ADC) injection HS-20093 to be included as a breakthrough therapy. The intended indication is for locally advanced or metastatic non-squamous non-small cell lung cancer that is driven by gene-negative and has progressed or relapsed after previous platinum-based chemotherapy. HS-20093 is a B7-H3 targeted ADC, composed of a fully human anti-B7-H3 monoclonal antibody and a topoisomerase inhibitor.

Gelonghui FinanceApr 17 08:16 ET

Express News | Hansoh Pharmaceutical - Nmpa Granted Breakthrough-Therapy-Designated-Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093

ReutersApr 17 08:13 ET

Has the SSE Health Care theme Index risen again? This year, the public fund performance has shuffled, with the highest return of the health care theme Fund exceeding 44%, and Inflow of capital has accelerated.

As of April 16, two SSE Health Care theme Index Funds have entered the top 10 performances of actively managed equity funds this year; Since April, multiple Hwabao WP CSI Medical Service ETFs have seen significant net subscriptions, with the total amount of fund shares for these medical ETFs reaching a new high; Fund managers believe that the pharmaceutical sector is not just undervalued in parts, but is comprehensively undervalued, and the nature of Innovative Drugs has changed.

cls.cnApr 16 20:31 ET

Hansoh Pharma Gets Clinical Trial Nod in China for Cancer Drug

MT NewswiresApr 16 02:13 ET